Horizon Pharma to buy Hyperion Therapeutics
March 30, 2015 at 07:28 AM EDT
Horizon Pharma agrees to buy Hyperion Therapeutics for $955.7 million, or $46 a share, in cash as it looks to expand its drug portfolio.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.